Companies / Climb Bio, Inc.

Climb Bio, Inc.

Nasdaq: CLYMCIK 1768446WELLESLEY HILLS, MA

Financials

Revenue—
Net income$-59.85M
Total debt—
Cash$44.11M
Diluted EPS$-0.88
Shares outstanding57.4M

Ownership

57.4M shares outstanding · as of Jul 31, 2026
4.7%10%+ / strategic
Ownership
10%+ / strategic4.65%2,671,480
Institutions56.98%32,725,418
Public float38.37%22,039,357

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 14

View all →
Insider% of sharesShares
RA Capital Management, L.P.FormerDirector · 10% owner
5.93%3,403,429
Thomas Stephen BasilFormerDirector
0.27%154,657
ALTSCHULLER SusanChief Financial Officer
——
Brennan AoifeCEOPresident and CEO · Director
——
Drapkin Kimberlee CDirector
——
Driscoll CindyFormerSenior Vice President, Finance
——
Kolchinsky PeterFormerDirector · 10% owner
——
RA Capital Healthcare Fund LPFormerDirector · 10% owner
——
RA Capital Nexus Fund III, L.P.FormerDirector · 10% owner
——
RA Capital Nexus Fund II, L.P.FormerDirector
——

Institutional holders 68

View all →
HolderValue% of shares
RA Capital Management, L.P.$77.41M19.68%
BlackRock, Inc.$30.71M4.10%
MPM BioImpact LLC$10.69M4.65%
Great Point Partners, LLC$9.14M2.32%
State Street Corporation$8.96M1.20%
Millennium Management LLC$8.74M2.22%
ADAR1 Capital Management, LLC$5.73M2.49%
Vanguard Group Inc$5.36M2.33%
Marshall Wace, LLP$5.30M1.35%
Affinity Asset Advisors, LLC$5.20M2.26%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Feb 12, 2026Thomas Stephen Basil
Director
SellCommon Stock$471.0K-90K
-29.54%
214,657
0.37% of shares
medium
Feb 25, 2026Thomas Stephen Basil
Director
SellCommon Stock$236.0K-34K
-16.46%
170,970
0.30% of shares
medium
Feb 26, 2026Thomas Stephen Basil
Director
SellCommon Stock$114.3K-16K
-9.54%
154,657
0.27% of shares
medium
Feb 13, 2026Thomas Stephen Basil
Director
SellCommon Stock$58.1K-10K
-4.66%
204,657
0.36% of shares
low
Jan 5, 2026RA Capital Management, L.P.
Director
BuyCommon Stock$24.9K+7K
+0.21%
3,403,429
5.93% of shares
low
Jun 5, 2026Drapkin Kimberlee C
Director
GrantStock Option (Right to Buy)—+40K
40,000
0.07% of shares
low
Jun 5, 2026RA Capital Management, L.P.
Director
GrantStock Option (Right to Buy)—+40K
40,000
0.07% of shares
low
Apr 29, 2026RA Capital Management, L.P.
Director
GrantPre-Funded Warrants (Right to Buy)—+2.1M
+10.30%
22,546,000
39.25% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
MPM BioImpact LLCPassive13G—2,671,480—

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
CLYMCommon StockEquity28658R106BBG00ZNKL0K6